Diagnosing Dx

In this episode of Diagnosing Dx, David Filby is joined by Talia Cohen Solal, CEO at NeuroKaire . Talia is a neuroscientist by training who spent more than a decade in academia, including time at Oxford , UC L, and Columbia , before moving into the startup world to get closer to real patient impact. In this conversation, we explore why precision medicine has transformed fields like oncology but st...

In this episode of Diagnosing Dx, David Filby is joined by Bharat Tewarie, MD, MBA, CEO at Helio Genomics .   Bharat has led Helio Genomics since July 2025, bringing decades of global healthcare leadership across pharma, biotech, diagnostics, and digital health. In this conversation, we explore why liver cancer surveillance still relies too heavily on outdated imaging, why so many high-risk patien...

In this episode of Diagnosing Dx, I’m joined by Jonathan Romanowsky, co-founder of Inflammatix and Principal at Kadima Spark. Jonathan shares lessons from leading diagnostics launches at CareDx, CardioDX, Veracyte, and Inflammatix. We discuss commercialization, reimbursement, fundraising, and why startups need to think about market adoption much earlier than before. We also explore Inflammatix’s e...

In this episode of Diagnosing Dx, I’m joined by Svetlana Nikic, Founder of Precision Oncology Consulting. Svetlana shares her journey from Roche and Illumina into building her own consultancy focused on helping diagnostics companies navigate the realities of market access in Europe. We explore the gap between innovation and implementation, why strong science alone does not guarantee patient access...

In this episode of Diagnosing Dx, I’m joined by Sara Barrington, CEO at Verici Dx. Sara explains how Verici Dx is tackling one of the biggest unresolved problems in kidney transplant care: helping clinicians monitor patients more precisely after transplant without relying so heavily on biopsies and legacy testing. We explore why balancing rejection risk against unnecessary immunosuppression is so...

In this episode of Diagnosing Dx, I’m joined by Arnon Chait, PhD, MBA, Chief Innovation Officer at Cleveland Diagnostics. Arnon shares his journey from NASA physicist to diagnostics innovator, and explains how Cleveland Diagnostics tackled one of the biggest challenges in prostate cancer testing: turning a widely used but flawed marker like PSA into something more clinically useful. We explore the...

In this episode of Diagnosing Dx, I’m joined by Serge Saxonov, Co-founder and CEO of 10x Genomics, a leader in single cell and spatial biology. Serge shares the story behind 10x Genomics, the evolution of its foundational technologies, and the launch of Atera, a new platform designed to enable whole transcriptome analysis in tissue at scale with single cell level sensitivity. We explore why biolog...

In this episode of Diagnosing Dx, I’m joined by Nathalya Mamane, Co-Founder and CEO at Anywhere Dx. Nathalya shares the origin story behind Anywhere Dx and how a personal pain point led her to build a diagnostics company focused on bringing molecular testing into the home. We explore why the current standard of care for infectious disease testing is still too slow, too expensive, and too dependent...

In this episode of Diagnosing Dx, I’m joined by MJ Hymes, Managing Partner at i5 BioPartners. MJ shares his journey from molecular biology into the commercial side of life sciences, and explains why great science alone is rarely enough to build a successful diagnostics or biotech company. We explore the gap between innovation and execution, why so many early-stage companies struggle to turn promis...

In this episode of Diagnosing Dx, I’m joined by Ajit Singh, CEO at Harbinger Health. Ajit has spent decades building, scaling, and investing in diagnostics companies, and this conversation draws on that full perspective. We explore why cancer diagnosis remains one of the biggest unresolved problems in care, what happens after suspicion enters the system, and why so many patients still face delays,...

This week I’m joined by Yana Aznavour, MD, PhD, OB-GYN surgeon and Founder & CEO of Endometrics. We unpack one of the biggest failures in modern healthcare: why women are still waiting up to 11 years for an endometriosis diagnosis, why the current standard still relies on surgery, and what it takes to build a diagnostic that clinicians will actually trust and use. This conversation goes beyond...

In this episode of Diagnosing Dx, I’m joined by Maria Zannes, Chief Executive Officer and Director at bioAffinity Technologies. Maria shares her journey from journalism and business leadership into diagnostics, and explains how bioAffinity Technologies is building a non-invasive platform for lung disease diagnosis, starting with early lung cancer detection. We explore the limitations of current pa...

In this episode of Diagnosing Dx, I’m joined by ⁠ Garreth Hippe ⁠, Chief Commercial Officer at ⁠GenomOncology ⁠, a software company helping turn complex genomic data into faster, more actionable decisions in oncology. Garreth has spent much of his career in clinical genomics, bioinformatics, and healthcare software, and in this conversation we explore how the field has evolved over the last 20 yea...

In this first episode of Diagnosing WDx, the new women’s health-focused sister series from Diagnosing Dx, I’m joined by Marra Francis, MD , board-certified OB-GYN, women’s health expert, and advisor to multiple early-stage diagnostics companies. Recorded in the week of International Women’s Day, this conversation explores one of the biggest blind spots in healthcare: the historic and ongoing gap i...

In this episode of Diagnosing Dx, I’m joined by ⁠ Tammy Crawford⁠ , Chief Executive Officer, and ⁠ Holly Ahern ⁠, Chief Scientific Officer at ⁠ Aces Diagnostics ⁠, a company building what could become the first highly accurate test across all stages of Lyme disease. We explore why early Lyme is so often missed, the myth of the bullseye rash, and the structural gaps in today’s testing pathway. Tamm...

In this episode of Diagnosing Dx, I’m joined by ⁠ Spencer Price ⁠, Chief Executive Officer at ⁠ OraLiva ⁠, a company building an AI-powered precision diagnostic designed to transform oral cancer detection and shift the standard of care. We explore Spencer’s unconventional move from autonomous vehicles into diagnostics, why OraLiva built commercialisation and reimbursement strategy into the company...

In this episode of Diagnosing Dx, I’m joined by Jake Lesinski , Co-founder and CEO of Checktor Biosciences , an ETH Zurich spin-out building a CRISPR-based chemistry platform designed to upgrade existing diagnostic systems rather than replace them. We explore why speed, decentralisation, and practical integration, not hype, will define the next wave of molecular diagnostics. Jake shares how Checkt...

In this episode of Diagnosing Dx, I’m joined by Zivjena Vucetic , Chief Medical Officer at Mission Bio , to explore what it really takes to turn breakthrough diagnostics science into tools that change clinical decisions. With nearly two decades across oncology, neurology, infectious disease, and single-cell technologies, Zivjena shares a rare perspective on the messy middle of diagnostics, where g...

In this episode of Diagnosing Dx, I’m joined by Unika Alexander, Co-Founder and CEO of The Proficient Lab, to unpack what’s really happening inside today’s diagnostic labs and why many are under more pressure than ever. This conversation goes beyond hype to look at the operational reality of diagnostics — from compliance and reimbursement challenges to why modern labs need better data visibility t...

In this episode of Diagnosing Dx, I’m joined by Rachel Zayas, CEO of AGED Diagnostics, a company tackling one of the most underdiagnosed and overlooked conditions in healthcare: liver disease. Rachel shares what it really takes to build a diagnostics company from scratch in a high-friction clinical space, why liver disease is so difficult to detect early, and how systemic gaps in specialist access...

In this episode of Diagnosing Dx, I’m joined by Harald Steltzer , CEO of OrisDX , a company tackling one of the most overlooked gaps in diagnostics: early detection of head and neck cancer. Harald shares his journey from biochemistry and genetics into startup leadership, and why dentistry may be one of the most overlooked frontlines for early cancer detection today. We explore how OrisDX is rethin...

In this episode of Diagnosing Dx, I sit down with Frédéric D. Sweeney, President & CEO of VedaBio, the company pioneering a completely new class of molecular diagnostics — one that detects DNA and RNA without amplification while maintaining full clinical sensitivity in under 10 minutes. We explore how this platform could transform urgent care, decentralised testing, and infectious disease work...

In this episode, Dr. Russ Lebovitz, CEO of Amprion, explains why detecting misfolded proteins years before symptoms begin could completely reshape how we diagnose Alzheimer’s, Parkinson’s, and other neurodegenerative diseases.   He breaks down how early detection unlocks new possibilities for intervention, why alpha-synucleinis such a powerful biomarker, and what it really takes to commercialise a...

In this episode of DiagnosingDx, I’m joined by Wissam Hamou, Chief Operating Officer of One Biosciences, a company bringing single-cell diagnostics out of the lab and into real clinical practice. We explore why single-cell analysis is finally ready for the clinic, how AI is unlocking insights that were previously impossible to see, and what this technology means for trials, treatment response, and...

In this episode of Diagnosing Dx, I’m joined by Mustafa Al-Adhami, CEO and founder of Astek Consulting.   We dive into how his team is building a rapid testing platform that can confirm a UTI, detect E. coli, and identify the right antibiotic within one hour - a breakthrough that has the potential to prevent sepsis and reshape frontline care.   We also explore the realities of building a diagnosti...